CD160 Ans Corneal Graft: Expression in Corneal Vessels
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Observational
SUMMARY
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18-year-old or more patients
• enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
Locations
Other Locations
France
Damien JOLLY
RECRUITING
Reims
Contact Information
Primary
Alexandre DENOYER
adenoyer@chu-reims.fr
03 26 78 78 88
Time Frame
Start Date: 2021-04-21
Estimated Completion Date: 2024-07-21
Participants
Target number of participants: 20
Treatments
HOSTS
patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor
DONORS
grafts from donors that would be analyzed
Related Therapeutic Areas
Sponsors
Leads: CHU de Reims